Mark Hamann to Depsipeptides
This is a "connection" page, showing publications Mark Hamann has written about Depsipeptides.
Connection Strength
3.633
-
Recent advances and limitations in the application of kahalalides for the control of cancer. Biomed Pharmacother. 2022 Apr; 148:112676.
Score: 0.763
-
An efficient and cost-effective approach to kahalalide F N-terminal modifications using a nuisance algal bloom of Bryopsis pennata. Biochim Biophys Acta. 2015 Sep; 1850(9):1849-54.
Score: 0.478
-
Computationally assisted assignment of kahalalide Y configuration using an NMR-constrained conformational search. J Nat Prod. 2013 Feb 22; 76(2):178-85.
Score: 0.408
-
In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities. Bioorg Med Chem. 2011 Nov 15; 19(22):6628-32.
Score: 0.365
-
Chemistry and biology of kahalalides. Chem Rev. 2011 May 11; 111(5):3208-35.
Score: 0.360
-
5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec; 72(12):2172-6.
Score: 0.328
-
Kahalalides V-Y isolated from a Hawaiian collection of the sacoglossan mollusk Elysia rufescens. J Nat Prod. 2008 May; 71(5):772-8.
Score: 0.293
-
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies. J Med Chem. 2007 Sep 06; 50(18):4340-50.
Score: 0.279
-
Technology evaluation: Kahalalide F, PharmaMar. Curr Opin Mol Ther. 2004 Dec; 6(6):657-65.
Score: 0.232
-
SB-224289 Antagonizes the Antifungal Mechanism of the Marine Depsipeptide Papuamide A. PLoS One. 2016; 11(5):e0154932.
Score: 0.128